New Developments in KRAS-Driven Cancer Treatment
Silexion Therapeutics Corp. (NASDAQ: SLXN) is making significant strides in the field of cancer treatment, particularly for pancreatic cancer, which is notoriously difficult to treat. As part of their commitment to advancing RNA interference (RNAi) therapies, the company announced its participation in a key oncology symposium aimed at sharing cutting-edge research.
Presentation at ASCO Gastrointestinal Symposium
At the upcoming ASCO Gastrointestinal Cancers Symposium happening soon, experts and oncologists will gather to discuss the latest findings in gastrointestinal cancer treatments. Silexion is poised to present their innovative SIL-204 therapy, which aims to address KRAS mutations that are prevalent in many cancers.
Importance of the Symposium
This meeting serves as a crucial forum for healthcare professionals to learn about the latest in oncology, particularly concerning new therapies and scientific advancements that can improve patient care. Silexion’s presence underscores its role in shaping future cancer treatments, especially for conditions driven by genetic mutations.
Key Presentation Details
During the symposium, the title of Silexion's presentation will be: SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation.
Dr. Mitchell Shirvan will be the lead presenter, providing insights into how this novel therapy works and its implications for treating severe cancers. The session, featuring this abstract numbered 745, is a part of a broader discussion on cancers affecting the pancreas, small bowel, and hepatobiliary tract.
Scientific Insights into SIL-204
SIL-204 represents a groundbreaking approach to targeting cancer cells that exhibit specific KRAS mutations. The therapy aims to enhance the precision of treatment for patients suffering from these challenging cancer types. Clinical trials are being conducted, showing optimism around SIL-204’s efficacy based on preclinical data.
About Silexion Therapeutics
Silexion Therapeutics has emerged as a pioneering entity in the biotechnology sector, specifically dedicated to the development of RNAi therapies for the treatment of solid tumors driven by KRAS mutations. This pivotal oncogenic driver is among the most common targets in cancer therapy development today.
The company’s first-generation product, LODER™, has demonstrated promising results in patients with non-resectable pancreatic cancer during Phase 2 clinical trials. Silexion is committed to exploring innovative methods to expand its therapeutic offerings to address even more KRAS mutations effectively.
Future Prospects in Oncology
Silexion’s ongoing research and development are set against the backdrop of a rapidly evolving oncology landscape. With significant investments in therapeutic innovation, the company aims to improve survival rates and quality of life for patients assigned to difficult-to-treat cancer categories. Their unwavering focus reflects a broader trend in biotechnology to transform how cancer is approached and managed.
Company Contact Information
For further information regarding Silexion Therapeutics and their developments, interested parties should reach out via the following:
Company Name: Silexion Therapeutics Corp
Name: Ms. Mirit Horenshtein Hadar, CFO
Email: mirit@silexion.com
Capital Markets & IR Contact:
ARX | Capital Markets Advisors
North American Equities Desk
Email: silexion@arxadvisory.com
Frequently Asked Questions
What is SIL-204?
SIL-204 is an innovative RNAi therapy developed by Silexion Therapeutics specifically designed to target KRAS mutations in cancer treatment.
Where will SIL-204 be presented?
SIL-204 will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium.
Who is presenting the poster for SIL-204?
The poster will be presented by Dr. Mitchell Shirvan at the symposium.
What does RNA interference therapy do?
RNA interference therapy works by silencing specific genes involved in cancer growth, thereby inhibiting the progression of the disease.
How can I learn more about Silexion Therapeutics?
You can learn more about Silexion Therapeutics and their research by visiting their official website or contacting them directly via the provided details.
